VistaGen Therapeutics (VTGN) Set to Release Quarterly Earnings on Thursday

VistaGen Therapeutics (NASDAQ:VTGN) is expected to be issuing its Q2 2027 results before the market opens on Thursday, November 12th. Analysts expect VistaGen Therapeutics to announce earnings of ($0.3750) per share and revenue of $0.50 million for the quarter. Individuals can check the company’s upcoming Q2 2027 earnings results page for the latest details on the call scheduled for Thursday, November 12, 2026 at 5:00 PM ET.

VistaGen Therapeutics (NASDAQ:VTGN) last issued its quarterly earnings results on Friday, August 14th. The company reported ($0.30) EPS for the quarter, topping the consensus estimate of ($0.36) by $0.06. The firm had revenue of $1.48 million during the quarter, compared to analyst estimates of $0.50 million. VistaGen Therapeutics had a negative net margin of 2,702.64% and a negative return on equity of 152.59%. On average, analysts expect VistaGen Therapeutics to post ($1.45) EPS for the current fiscal year and ($1.54) EPS for the next fiscal year.

VistaGen Therapeutics Price Performance

Shares of NASDAQ:VTGN opened at $0.18 on Thursday. VistaGen Therapeutics has a 12 month low of $0.17 and a 12 month high of $5.14. The business has a 50-day moving average of $0.23 and a two-hundred day moving average of $0.44. The firm has a market capitalization of $8.18 million, a PE ratio of -0.11 and a beta of 0.49.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of VistaGen Therapeutics in a report on Monday, August 31st. Four investment analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Reduce” and an average target price of $0.95.

VistaGen Therapeutics Company Profile

Vistagen Therapeutics, Inc (NASDAQ: VTGN) is a clinical-stage biopharmaceutical company developing therapies for central nervous system and neuropsychiatric disorders. The company focuses on intranasal treatments designed to act rapidly and address conditions for which patients may need alternatives to conventional systemic medicines.

Vistagen’s lead investigational product is fasedienol, also known as PH94B, a nasal spray being studied as a potential treatment for social anxiety disorder.